News & Events

Category: COVID-19 21 April 2021

Author

Richmond Research Institute asks the question, 'Do post-COVID-19 patients need a second dose of vaccine?'

Richmond Research Institute is actively involved in COVID-19 symptoms testing for all staff and visitors who attempt entry to Richmond Pharmacology's London bridge clinical trial unit. The data accumulated throughout this period before and after vaccination has led to the following publication: 'Do post-COVID-19 patients need a second dose of vaccine?

Read more ...

Category: COVID-19 19 April 2021

Author

Do we still need challenge trials with COVID-19?

A response to a Human Challenge statement in the BMJ by Nir Eyal and colleagues.

Read more ...

Category: Press Releases 11 April 2021

Author

Accelero contributes tp CombiGene AB’s Gene Therapy Program for Epilepsy

Accelero is proud becoming a selected partner for the leading Nordic gene therapy company CombiGene AB (Lund) developing an AAV-based treatment targeting epilepsy.

Read more ...

Category: Publications 6 April 2021

Author

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.

Read more ...

Category: Publications 18 March 2021

Author

A new era for UK-Japanese scientific relations

As the UK and Japan embark on a new trade deal, there are aspirations of greater collaboration and investment between the two nations. Dr Jorg Taubel shares his thoughts on the future needs of the Japanese pharmaceutical market and how UK-Japanese scientific relations can support this in his recent article in the Pharmaceutical Market Europe and PMLive.

Read more ...

Category: Press Releases 19 February 2021

Author

Accelero Receives EU Eurostars Funding Supporting a Gene Therapy for the Treatment of Lypodystrophy

Accelero Bioanalytics GmbH (“Accelero”) is awarded EUR 136,500 in project grants to support research and development of a gene therapy targeting lypodystrophy.

Read more ...

Category: Publications 19 January 2021

Author

Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.

Co-authored by Christian Wolf

Benedict RHB, Tomic D, Cree BA, Fox R, Giovannoni G, Bar-Or A, Gold R, Vermersch P, Pohlmann H, Wright I, Karlsson G, Dahlke F, Wolf C, Kappos L.

Neurology. 20219; 96:e376-e386. https://doi.org/10.1212/WNL.0000000000011275.

 

Category: Publications 18 November 2020

Author

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis

Co-authored by Christian Wolf

Cree BA, Magnusson B, Rouyrre N, Fox RJ, Giovannoni G, Vermersch P, Bar-Or A, Gold R, Piani Meier D, Karlsson G, Tomic D, Wolf C, Dahlke F, Kappos L.

Multiple Sclerosis Journal 2020; Nov 18:1352458520971819, https://doi.org/10.1177/1352458520971819 (open access).

Category: Press Releases 10 November 2020

Author

Marking a milestone for gene editing

We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001.

Read more ...

Category: Events 2 September 2020

Author

From Target to Market

The GLA Biotech & Pharma Summer School

Michael Hildebrand, Wolf-Stefan Richter und Jens Hoffmann will present at "From Target to Market – The GLA Biotech & Pharma Summer School" from 2nd to 5th of September in Berlin.

https://www.glaesernes-labor-akademie.de/de/biotech-pharma